Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. (Q34434935)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

case report

0 references

title

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Manlio Tolomeo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Claudia Colomba

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Raffaella Rubino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Lucia Siracusa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Francesco Lalicata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Lucina Titone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

5 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

552

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 2.0 Generic

9 March 2020

copyright license

start time

5 October 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

A gain-of-function mutation of JAK2 in myeloproliferative disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

Cellular responses to interferon-gamma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3515333

27 October 2018

Identifiers

DOI

10.1186/1756-0500-5-552

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

PubMed publication ID

23039051

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039051%20AND%20SRC:MED&resulttype=core&format=json